A Study of the TheraBionic P1 Device in Breast Cancer

A Window of Opportunity Pilot Study: TheraBionic P1 Device for Patients With Resectable Early-stage Breast Cancer in a Neoadjuvant Setting

The goal of this clinical trial is to learn if adding cancer-specific amplitude-modulated radiofrequency electromagnetic field therapy (TheraBionic P1 device) to the treatment of resectable early-stage breast cancer will affect the pathological response.

Study Overview

• Status: Recruiting
• Conditions: Breast Cancer Stage I; Breast Cancer Stage II; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Breast Cancer Stage IIIA
• Intervention / Treatment: Device: TheraBionic P1 Device

• Study Type: Interventional
• Enrollment (Estimated): 24
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Lubina Arjyal, M.D.; Phone Number: 1-800-karmanos; Email: arjyall@karmanos.org

Study Locations

• United States
  • Michigan
    • Clarkston, Michigan, United States, 48346
      • Recruiting
      • Karmanos Cancer Institute at McLaren Clarkston
      • Contact: Phone Number: 248-922-6650
    • Detroit, Michigan, United States, 48201
      • Recruiting
      • Karmanos Cancer Institute
      • Contact: Lubina Arjyal, MD; Phone Number: 1-800-527-6266; Email: arjyall@karmanos.org
    • Farmington Hills, Michigan, United States, 48334
      • Recruiting
      • Karmanos Cancer Institute Weisberg Cancer Treatment Center
      • Contact: Phone Number: 1-800-527-6266
    • Flint, Michigan, United States, 48532
      • Recruiting
      • Karmanos Cancer Institute at McLaren Flint
      • Contact: Phone Number: 810-342-3800
    • Lansing, Michigan, United States, 48910
      • Recruiting
      • Karmanos Cancer Institute at McLaren Greater Lansing
      • Contact: Phone Number: 517-975-9500
    • Lapeer, Michigan, United States, 48466
      • Recruiting
      • Karmanos Cancer Institute at McLaren Lapeer Region
      • Contact: Phone Number: 810-667-4994
    • Petoskey, Michigan, United States, 49770
      • Recruiting
      • Karmanos Cancer Institute at McLaren Northern Michigan
      • Contact: Phone Number: 231-487-3390
    • Port Huron, Michigan, United States, 48060
      • Recruiting
      • Karmanos Cancer Institute at McLaren Port Huron
      • Contact: Phone Number: 810-982-5200

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participant must have histologically proven invasive breast cancer that is HR (hormone receptor) positive and HER2 (Human Epidermal Growth Factor Receptor 2) negative according to the 2010 American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines (ER and/or PR (progesterone receptor) >1% and HER2 negative by immunohistochemistry [IHC] and/or fluorescent in situ hybridization [FISH]).
• Participant must have early-stage operable disease (stage I-II or III who have planned upfront surgery) and agree to definitive upfront surgery.
• Participant must be available for at least two weeks of TheraBionic treatment prior to scheduled resection
• Participant must have archival tissue available.
• Participant must be a woman aged 22 years or older
• Participant must be able to understand a written informed consent document and be willing to sign it
• Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
• It is not known what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, women of child-bearing potential must agree to avoid becoming pregnant starting at initiation of treatment up until at least 30 days after the last TheraBionic P1 session

Exclusion Criteria:

• Participants that are receiving or will receive neoadjuvant chemotherapy or neoadjuvant hormonal therapy
• Participants with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints
• Participants that are taking any other investigational drugs
• Participants that are pregnant or breastfeeding due to the unknown but potential risk for adverse events. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued
• Participants with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of TheraBionic P1 device (for example: mucositis, thrush, bleeding mucosal lesions, oral herpes, aphthous stomatitis, mouth ulcers, chancre sores, gingivostomatitis, herpangina, aphthae).
• Participants receiving calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels (for example: amlodipine, nifedipine, ethosuximide, ascorbic acid/vitamin C, etc.) unless their medical treatment is discontinued at least one day prior to treatment. Participant must agree to abstain from using calcium channel blockers for the duration of treatment on study.
• Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device
• Participants with a known severe (e.g., anaphylactic) allergy to nickel.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TheraBionic P1 device; Self Administered Amplitude-modulated electromagnetic fields three times daily	Device: TheraBionic P1 Device; Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day and in the evening prior to surgical resection of early stage breast cancer.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pathological Response to Treatment	Proportion of responders based on residual cancer cells in a resection specimen will be quantified. The response rate will be estimated as the proportion of patients who respond to treatment relative to all patients. The corresponding two-sided 95% confidence interval (CI) will be calculated using Clopper and Pearson's method	At time of surgery (after approximately 2 weeks of treatment and tumor resection)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in microRNA expression in tumor tissue	Changes in microRNA expression in tumor tissue pre- and post-treatment will be calculated as the difference between pre- and post-treatment expression values with two-sided 95% CI estimated using a standard t-distribution-based formula for paired differences.	Baseline to post-surgical resection
Changes in Ki-67 expression in tumor tissue	Changes in Ki-67 expression in tumor tissue pre- and post-treatment will be calculated as the difference between pre- and post-treatment expression values with two-sided 95% CI estimated using a standard t-distribution-based formula for paired differences.	Baseline to post-surgical resection
Changes in tumor apoptosis marker Cleaved caspase-3 (CC3) in tumor tissue	Changes in CC3 expression in tumor tissue pre- and post-treatment will be calculated as the difference between pre- and post-treatment expression values with two-sided 95% CI estimated using a standard t-distribution-based formula for paired differences.	Baseline to post-surgical resection
Changes in cell cycle arrest marker p27 in tumor tissue	Changes in p27 expression in tumor tissue pre- and post-treatment will be calculated as the difference between pre- and post-treatment expression values with two-sided 95% CI estimated using a standard t-distribution-based formula for paired differences.	Baseline to post-surgical resection
Overall survival (OS)	OS will be graphically summarized using Kaplan-Meier (KM) curves, with corresponding medians and two-sided 95% CIs computed using KM estimates. Additionally, OS rates at every six months post-treatment will be estimated using the KM estimated, with two-sided 95% CIs provided for each time point.	Up to 5 years post-surgery
Progression Free Survival (PFS)	PFS will be graphically summarized using Kaplan-Meier (KM) curves, with corresponding medians and two-sided 95% CIs computed using KM estimates. Additionally, PFS rates at every six months post-treatment will be estimated using the KM estimated, with two-sided 95% CIs provided for each time point.	Up to 5 years post-surgery

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Positron Emission Tomography with 3'-Deoxy-3'-18F-Fluorothymidine (PET-FLT) association of response to treatment	Changes in the SUV max as measured by FLT-PET prior to treatment compared to after treatment and before resection. SUV (standard uptake value) max values will be log-transformed and descriptively summarized using the mean, standard deviation, and two-sided 95% CI. Changes in SUV max pre- and post-treatment will be calculated as the difference between the pre- and post-treatment values with two-sided 95% CI estimated using a standard t-distribution-based formula for paired differences. The association between changes in SUV max and response will be explored using logistic regression analysis. Optional study for the first 5 participants.	From Screening to after 7 days of treatment with the TheraBionic Device.

Collaborators and Investigators

• Sponsor: Barbara Ann Karmanos Cancer Institute
• Investigators: Principal Investigator: Lubina Arjyal, M.D., Wayne State University

Study record dates

Study Major Dates

• Study Start (Estimated): October 1, 2026
• Primary Completion (Estimated): April 30, 2027
• Study Completion (Estimated): June 30, 2028

Study Registration Dates

• First Submitted: September 9, 2025
• First Submitted That Met QC Criteria: October 16, 2025
• First Posted (Actual): October 20, 2025

Study Record Updates

• Last Update Posted (Actual): April 21, 2026
• Last Update Submitted That Met QC Criteria: April 16, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Skin Diseases; Breast Diseases; Skin and Connective Tissue Diseases; Breast Neoplasms
• Other Study ID Numbers: 2025-026

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No